The agent mesh + experimental graph + LIMS-native integration described in Section 06. Sold as: (a) LabOS Platform — annual subscription per site, agent mesh + capability registry + LIMS adapters; (b) LabOS Bench — full LIMS replacement module for greenfield sites; (c) LabOS Broker — usage-based execution routing across partner CROs.
Self-serve multiomics pipeline — WGS/WES, scRNA-seq, spatial, proteomics. India reference genome integration. Frontier-LLM agents Year 1; India-tuned bio model Year 2+. Target: biotech startups, academic institutions, hospital research arms that don't yet need LabOS execution layer.
Time-boxed, milestone-defined discovery programs powered by LabOS end-to-end. 90-day to 18-month engagements. Two flagship sprint products — IVD Companion Diagnostics & Phase 4 Pharmacovigilance — fully costed in Section 12.
Proprietary biomarker database built on the Apollo Hospitals biobank substrate. Licensed to pharma for companion Dx development, clinical trial design, patient stratification. Revenue share with Apollo.
Regulatory-grade dossiers for CDSCO, TGA, PMDA, FDA. IND-enabling preclinical reports. IVD submission packages. Phase 4 PV signal reports. Bridging study design for India populations.
Equity + milestone deals with pharma/biotech. We provide full LabOS infrastructure + Apollo data access; they provide disease area focus and commercial execution. Revenue + IP sharing. Royalty streams at Phase 2+.
LabOS is the only platform that treats every experiment as a typed, provenance-signed graph. The graph unifies sample lineage, data lineage, regulatory audit trail, and agent training data into a single substrate. Once we are the system of record for a lab's experimental graph, displacing us means re-validating every protocol — the same switching-cost moat that protects STARLIMS, flipped to favor us.
The Apollo partnership (Section 05) gives us pan-India EHR + consented biospecimens + clinical phenotyping that no global competitor can replicate by writing a check. India harbors ~4,600 population groups; Apollo touches all of them. The India Biomarker Atlas built on this substrate is the genomic Rosetta Stone for Asia — a 3–5 year structural lead.
Pure software plays (Isomorphic, Schrödinger) need wet lab partners. Pure CROs lack AI depth. Pure FAL owners (Ginkgo) bleed capital. We bridge all three — agentic design + orchestrated wet-lab validation + clinical-grade data — delivered as a service. Recursion-class capability without Recursion-class infrastructure costs.
Native bridging across CDSCO, DCGI, the New Drugs and Clinical Trials Rules 2019, DPDP Act 2023, and ICMR genomic data guidelines. Most global platforms are FDA/EMA-optimized and treat India as a translation problem. We are the translation layer.
Year 1 LabOS runs on frontier LLMs behind a model-router that captures every trajectory as distillation data. By Year 2, an India-cohort-tuned bio model deployed on AWS Hyderabad and Apollo on-prem nodes serves 80% of agent calls. By Year 3, vertical-specialist models per disease area become licensable assets. This is both a margin lever (offload from frontier APIs) and a DPDP Act compliance feature — Apollo patient data never leaves India. No other India platform is architected for this from day one.